Effects of recombinant human recombinant interleukin-10 on proliferation and cell cycle of rat vascular smooth muscle cells
- Author:
Ping OU-YANG
1
Author Information
1. College of Life Science, Sun Yat-Sen University
- Publication Type:Journal Article
- Keywords:
Cell proliferation;
Cytokine;
Growth factor;
Recombinant interleukin-10;
Vascular smooth muscle cells
- From:
Chinese Pharmacological Bulletin
2002;18(2):190-193
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To determine the effects of recombinant human interleukin-10 (rhIL-10) on rat vascular smooth muscle cells (VSMCs) proliferation by platelet derived growth factor and tumor necrosis factor-α. METHODS: Rat aortic VSMCs were cultured and treated with rhIL-10 or tumor necrosis factor-α (TNF-α) or platelet-derived growth factor-BB (PDGF-BB) respectively. Proliferation was quantified by colormetric assay. Cell cycle analysis was performed by flow cytomertry. RESULTS: Compared with control, TNF-α and PDGF-BB can stimulated VSMCs proliferation, respectively. rhIL-10 alone had no effect on VSMCs growth. With TNF-α stimulation, rhIL-10, at dose as low as 10 μg·L-1, inhibited VSMCs growth (P < 0.05). With PDGF-BB stimulation, rhIL-10, at dose as low as 10 ng·L-1, inhibited VSMCs growth (P < 0.05). Cell number in G0/G1 phase of PDGF-BB and rhIL-10 co-treatment group was higher than those of PDGF-BB group (P < 0.01) by flow cytometry analysis. The same results were observed in TNF-α and rhIL-10 co-treatment group (P < 0.01). CONCLUSION: The class II cytokine receptor ligand, IL-10, inhibits TNF-α and PDGF-BB induced VSMCs proliferation, respectively. The class II cytokine receptor may provide a novel therapeutic target in regulating vessel wall remodeling after vascular injury.
